Australia markets closed

Celldex Therapeutics, Inc. (CLDX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
38.77+2.35 (+6.45%)
At close: 04:00PM EST
38.77 0.00 (0.00%)
After hours: 04:01PM EST
Full screen
Trade prices are not sourced from all markets
Previous close36.42
Open36.81
Bid0.00 x 1300
Ask0.00 x 1200
Day's range36.81 - 39.22
52-week range15.37 - 57.20
Volume366,500
Avg. volume427,769
Market cap1.809B
Beta (5Y monthly)2.75
PE ratio (TTM)N/A
EPS (TTM)-1.76
Earnings date09 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est65.17
  • GlobeNewswire

    Celldex Presents Positive Preclinical Data from PD-1/ILT4 Bispecific Antibody Program CDX-585 at SITC 2021

    HAMPTON, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced positive preclinical data from CDX-585, the Company’s bispecific antibody with dual targeting of ILT4 and PD-1 checkpoint pathways, developed from its bispecific antibody platform. These data were presented in a poster session as part of the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021). The data show CDX-585 effectively combines the blockade of ILT4 and PD-1 into one

  • GlobeNewswire

    Celldex to Participate in Upcoming Investor Conferences

    HAMPTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following virtual investor conferences in November: Guggenheim 3rd Annual Healthcare Talks Neuro/Immunology Conference on Tuesday, November 16, 2021 at 10:20 a.m. ETJefferies London Healthcare Conference available on-demand beginning Thursday, November 18, 2021 at 3:00 a.m. ET / 8:00 a.m. GMTEvercore ISI 4th Annual HealthCONx Conferen

  • Zacks

    Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates

    Celldex (CLDX) delivered earnings and revenue surprises of -11.43% and -91.02%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?